Gene-Drug link: study aims to personalize diabetes treatment
NCT ID NCT06003153
First seen Apr 06, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This study looks at how a person's genetic makeup influences their response to oral semaglutide, a drug used for type 2 diabetes. Researchers will give 125 people with prediabetes the drug for 14 days and measure blood sugar, fat, and protein levels after a standardized breakfast. The goal is to understand why some people respond differently to the same medication, which could lead to more personalized treatment in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral semaglutide
What this could lead to
If successful, this could help doctors personalize type 2 diabetes treatment based on a person's genetic makeup.
What could go wrong
This is a small, early-phase study focused on understanding mechanisms, not testing a new treatment. Results may not lead to immediate clinical changes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.